ClinicalTrials.gg
RecruitingNCT07894146VRCycling-ICUUpdated Oct 26, 2026

Cycling Within an Interactive and Immersive Virtual Environment During Critical Illness: a Patient-centred Approach for Lower Limb Rehabilitation

An interventional study of Basic-Cycle and TV-Cycle in Critical Illness, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by KU Leuven · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Oct 2026).
  • Started Jun 2026; still recruiting 3 months later.
Updated Oct 26, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to investigate whether combining cycling exercise with an immersive and interactive virtual reality (VR) environment improves motivation compared with cycling without visual support or cycling while watching a route on a television screen in critically ill patients admitted to the intensive care unit (ICU).

This randomized, within-subject crossover study will include 20 adult ICU patients who have been admitted for at least 7 days, have received mechanical ventilation for at least 48 hours, and are able to perform active cycling exercise.

Each participant will complete three 10-minute cycling sessions under different conditions: (1) cycling without visual support (Basic-Cycle), (2) cycling while watching a cycling route on a television screen (TV-Cycle), and (3) cycling within an immersive, interactive VR environment (VR-Cycle). The three conditions will be performed in random order over three consecutive days, with the cycling resistance kept constant across conditions for each participant.

The primary outcome is intrinsic motivation, assessed using the Situational Motivation Scale (SIMS). Secondary outcomes include other dimensions of motivation, perceived dyspnea, lower limb fatigue, pain, cycling distance, and safety measures, including vital signs and adverse events.

This study will provide insight into the potential of VR-assisted cycling to improve patient motivation and engagement during early rehabilitation in the ICU.

02

Conditions studied

  • Critical Illness

Browse trials for

03

In context

Critical Illness

1,924 studies on the registry are indexed under Critical Illness; 465 are open to participants now.

This study's planned enrollment of 20 is below the median of 90 across 1,003 interventional studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

KU Leuven is the lead sponsor of 372 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission to ICU ≥ 7 days
  • ≥ 48h mechanical ventilation
  • Expected additional ICU stay ≥ 7 more days
  • Adult (≥18y)
  • Awake and adequate
  • Alert and calm (RASS -1 to +1)
  • No medical contraindication for (bed-/chair-)cycling
  • Able to perform 10 minutes of active cycling

Exclusion criteria

Exclusion Criteria:

  • Significant visual impairments
  • Cognitive impairment (MMSE \< 20/30)
  • Psychotic disorder
  • Pregnancy
  • Not able to understand Dutch, French or English
  • Not able to provide informed consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Sequence 1: Basic-Cycle / TV-Cycle / VR-Cycle

    Behavioral: Basic-Cycle · Behavioral: TV-Cycle · Behavioral: VR-Cycle

  • Experimental
    Sequence 2: Basic-Cycle / VR-Cycle / TV-Cycle

    Behavioral: Basic-Cycle · Behavioral: TV-Cycle · Behavioral: VR-Cycle

  • Experimental
    Sequence 3: TV-Cycle / VR-Cycle / Basic-Cycle

    Behavioral: Basic-Cycle · Behavioral: TV-Cycle · Behavioral: VR-Cycle

  • Experimental
    Sequence 4: TV-Cycle / Basic-Cycle / VR-Cycle

    Behavioral: Basic-Cycle · Behavioral: TV-Cycle · Behavioral: VR-Cycle

  • Experimental
    Sequence 5: VR-Cycle / Basic-Cycle / TV-Cycle

    Behavioral: Basic-Cycle · Behavioral: TV-Cycle · Behavioral: VR-Cycle

  • Experimental
    Sequence 6: VR-Cycle / TV-Cycle / Basic-Cycle

    Behavioral: Basic-Cycle · Behavioral: TV-Cycle · Behavioral: VR-Cycle

Interventions

  • BehavioralBasic-Cycle

    Cycling without visual support

  • BehavioralTV-Cycle

    Cycling while viewing a cycling route on an external television screen

  • BehavioralVR-Cycle

    Cycling within an immersive, interactive virtual reality environment

06

What researchers measure

Primary outcomes

  1. Intrinsic Motivation

    Self-reported patient-reported outcome measured using the Intrinsic Motivation subscale of the Situational Motivation Scale (SIMS). It consists of four items rated on a 7-point Likert scale, ranging from 1 (does not correspond at all) to 7 (corresponds exactly). The subscale score is calculated as the mean of the four items, ranging from 1 to 7. Higher scores indicate greater intrinsic motivation and therefore a more favorable outcome.

    Time frame: Assessed following each cycling condition (max 20min cycling), on day 1, day 2 and day 3

Secondary outcomes

  1. Dyspnea

    Dyspnea sensation is assessed using the Modified Borg Dyspnea Scale (Borg CR10 Scale). This patient-reported scale measures the perceived intensity of breathlessness during cycling. Scores range from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores indicate greater perceived dyspnea and therefore a worse outcome.

    Time frame: Assessed following each cycling condition (max 20min cycling), on day 1, day 2 and day 3

  2. Lower limb fatigue

    Lower limb fatigue is assessed using the Modified Borg Dyspnea Scale (Borg CR10 Scale). This patient-reported scale measures the perceived intensity of leg fatigue during cycling. Scores range from 0 (no fatigue at all) to 10 (maximal fatigue). Higher scores indicate greater perceived lower limb fatigue and therefore a worse outcome.

    Time frame: Assessed following each cycling condition (max 20min cycling), on day 1, day 2 and day 3

  3. Pain

    Pain perception is assessed using the Visual Analog Scale (VAS). This patient-reported scale measures the perceived intensity of pain during cycling. Scores range from 0 (no pain at all) to 10 (worst imaginable pain). Higher scores indicate greater perceived pain intensity and therefore a worse outcome.

    Time frame: Assessed following each cycling condition (max 20min cycling), on day 1, day 2 and day 3

  4. Cycle distance

    An estimated cycle distance will be recorded during each cycling condition by the cycle ergometer in meters

    Time frame: Assessed following each cycling condition (max 20min cycling), on day 1, day 2 and day 3

  5. Identified Regulation

    Self-reported patient-reported outcome measured using the Identified Regulation subscale of the Situational Motivation Scale (SIMS). It consists of four items rated on a 7-point Likert scale, ranging from 1 (does not correspond at all) to 7 (corresponds exactly). The subscale score is calculated as the mean of the four items, ranging from 1 to 7. Higher scores indicate greater identified regulation, reflecting more autonomous motivation and therefore a more favorable outcome.

    Time frame: Assessed following each cycling condition (max 20min cycling), on day 1, day 2 and day 3

  6. External Regulation

    Self-reported patient-reported outcome measured using the External Regulation subscale of the Situational Motivation Scale (SIMS). It consists of four items rated on a 7-point Likert scale, ranging from 1 (does not correspond at all) to 7 (corresponds exactly). The subscale score is calculated as the mean of the four items, ranging from 1 to 7. Higher scores indicate greater externally controlled motivation, reflecting less autonomous motivation and therefore a less favorable outcome.

    Time frame: Assessed following each cycling condition (max 20min cycling), on day 1, day 2 and day 3

  7. Amotivation

    Self-reported patient-reported outcome measured using the Amotivation subscale of the Situational Motivation Scale (SIMS). It consists of four items rated on a 7-point Likert scale, ranging from 1 (does not correspond at all) to 7 (corresponds exactly). The subscale score is calculated as the mean of the four items, ranging from 1 to 7. Higher scores indicate greater amotivation and therefore a less favorable outcome.

    Time frame: Assessed following each cycling condition (max 20min cycling), on day 1, day 2 and day 3

Other outcomes

  1. Heart rate during cycling

    Heart rate is monitored before, during, and immediately after each cycling condition and expressed in beats per minute (bpm) to assess physiological responses and safety.

    Time frame: Immediately before, during (up to 20 minutes), and immediately after each cycling condition.

  2. Respiratory rate during cycling

    Respiratory rate is monitored before, during, and immediately after each cycling condition and expressed in breaths per minute to assess respiratory responses and safety.

    Time frame: Immediately before, during (up to 20 minutes), and immediately after each cycling condition.

  3. Peripheral oxygen saturation during cycling

    Peripheral oxygen saturation (SpO₂) is monitored using pulse oximetry before, during, and immediately after each cycling condition and expressed as a percentage (%) to assess oxygenation and safety.

    Time frame: Immediately before, during (up to 20 minutes), and immediately after each cycling condition.

  4. Systolic blood pressure during cycling

    Systolic blood pressure is measured before, during, and immediately after each cycling condition and expressed in millimeters of mercury (mmHg) to assess cardiovascular responses and safety.

    Time frame: Immediately before, during (up to 20 minutes), and immediately after each cycling condition.

  5. Diastolic blood pressure during cycling

    Diastolic blood pressure is measured before, during, and immediately after each cycling condition and expressed in millimeters of mercury (mmHg) to assess cardiovascular responses and safety.

    Time frame: Immediately before, during (up to 20 minutes), and immediately after each cycling condition.

  6. Mean arterial pressure during cycling

    Mean arterial pressure (MAP) is monitored before, during, and immediately after each cycling condition and expressed in millimeters of mercury (mmHg) to assess cardiovascular responses and hemodynamic safety.

    Time frame: Immediately before, during (up to 20 minutes), and immediately after each cycling condition.

  7. Adverse events

    Minor/major adverse events

    Time frame: Assessed during and after each cycling condition

07

Study locations

1 of 1 sites recruiting
  • University Hospitals Leuven
    Leuven, 3000, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07894146
Lead sponsor
KU Leuven
Responsible party
Daniel Langer (Associate professor Faculty of Movement and Rehabilitation Sciences, KU Leuven) — Principal investigator
First posted
Oct 26, 2026
Start date
Jun 29, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Daniel Langer, Associate professor
Contact
daniel.langer@kuleuven.be
+32 16 34 71 25

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion